Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Dec;147(6):1567–1574.

Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation.

D G Jamieson 1, D C Usher 1, D J Rader 1, E Lavi 1
PMCID: PMC1869946  PMID: 7495281

Abstract

Atherosclerosis is the leading cause of death and serious morbidity in economically developed societies through its sequelae of coronary artery and cerebrovascular disease. The causes and mechanisms of atherosclerosis are still largely unknown. Serum levels of a lipoprotein, Lp(a), have been shown, in retrospective and some prospective clinical studies, to be associated with increased risk of myocardial and cerebral infarction. The active part of Lp(a), apo(a), has > 80% homology with plasminogen; thus it may competitively inhibit the thrombolytic action of plasminogen and enhance thrombogenesis. Lp(a) has been shown to be deposited in the vascular wall of the aorta and coronary vessels, but its presence in the cerebral vessels has not yet been shown. Autopsy specimens of vessels of the circle of Willis from 23 patients were examined for degree of atherosclerosis and deposition of apo(a) by immunohistochemistry with apo(a)-specific monoclonal antibodies. The amount of apo(a) deposition in cerebral vessels correlated well with the degree of cerebral atherosclerosis. Arterial deposition of apo(a) was found entirely within the endothelial cell and subendothelial cell layers. There was no staining within the media and adventitia, with the exception of staining within the endothelial cells of the vasa vasorum. Correlation between the morphology of apo(a) deposition and plaque stage was found suggesting that detection of apo(a) in endothelial cells is an early event in the development of the atherosclerotic plaque of cerebral vessels.

Full text

PDF
1567

Images in this article

1570Figure 1
on p.1570

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERG K. A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. Acta Pathol Microbiol Scand. 1963;59:369–382. doi: 10.1111/j.1699-0463.1963.tb01808.x. [DOI] [PubMed] [Google Scholar]
  2. Beisiegel U., Niendorf A., Wolf K., Reblin T., Rath M. Lipoprotein(a) in the arterial wall. Eur Heart J. 1990 Aug;11 (Suppl E):174–183. doi: 10.1093/eurheartj/11.suppl_e.174. [DOI] [PubMed] [Google Scholar]
  3. Benditt E. P., Benditt J. M. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci U S A. 1973 Jun;70(6):1753–1756. doi: 10.1073/pnas.70.6.1753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Benditt E. P. Origins of human atherosclerotic plaques. The role of altered gene expression. Arch Pathol Lab Med. 1988 Oct;112(10):997–1001. [PubMed] [Google Scholar]
  5. Berg K., Dahlén G., Frick M. H. Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet. 1974;6(3):230–235. doi: 10.1111/j.1399-0004.1974.tb00657.x. [DOI] [PubMed] [Google Scholar]
  6. Dahlén G., Berg K., Frick M. H. Lp(a) lipoprotein/pre-beta1-lipoprotein, serum lipids and atherosclerotic disease. Clin Genet. 1976 Jun;9(6):558–566. doi: 10.1111/j.1399-0004.1976.tb01613.x. [DOI] [PubMed] [Google Scholar]
  7. Etingin O. R., Hajjar D. P., Hajjar K. A., Harpel P. C., Nachman R. L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991 Feb 5;266(4):2459–2465. [PubMed] [Google Scholar]
  8. Frick M. H., Dahlén G., Berg K., Valle M., Hekali P. Serum lipids in angiographically assessed coronary atherosclerosis. Chest. 1978 Jan;73(1):62–65. doi: 10.1378/chest.73.1.62. [DOI] [PubMed] [Google Scholar]
  9. Grainger D. J., Kemp P. R., Liu A. C., Lawn R. M., Metcalfe J. C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994 Aug 11;370(6489):460–462. doi: 10.1038/370460a0. [DOI] [PubMed] [Google Scholar]
  10. Grainger D. J., Kirschenlohr H. L., Metcalfe J. C., Weissberg P. L., Wade D. P., Lawn R. M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993 Jun 11;260(5114):1655–1658. doi: 10.1126/science.8503012. [DOI] [PubMed] [Google Scholar]
  11. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  12. Hayden M. R., Reidy M. Many roads lead to atheroma. Nat Med. 1995 Jan;1(1):22–23. doi: 10.1038/nm0195-22. [DOI] [PubMed] [Google Scholar]
  13. Hoefler G., Harnoncourt F., Paschke E., Mirtl W., Pfeiffer K. H., Kostner G. M. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis. 1988 Jul-Aug;8(4):398–401. doi: 10.1161/01.atv.8.4.398. [DOI] [PubMed] [Google Scholar]
  14. Hoff H. F., Bond M. G. Apolipoprotein B localization in coronary atherosclerotic plaques from cynomolgus monkeys. Artery. 1983;12(2):104–116. [PubMed] [Google Scholar]
  15. Hoff H. F., Heideman C. L., Gaubatz J. W., Scott D. W., Titus J. L., Gotto A. M., Jr Correlation of apolipoprotein B retention with the structure of atherosclerotic plaques from human aortas. Lab Invest. 1978 May;38(5):560–567. [PubMed] [Google Scholar]
  16. Hoff H. F., Heideman C. L., Gotto A. M., Jr, Gaubatz J. W. Apolipoprotein B retention in the grossly normal and atherosclerotic human aorta. Circ Res. 1977 Nov;41(5):684–690. doi: 10.1161/01.res.41.5.684. [DOI] [PubMed] [Google Scholar]
  17. Lindsberg P. J., Hallenbeck J. M., Feuerstein G. Platelet-activating factor in stroke and brain injury. Ann Neurol. 1991 Aug;30(2):117–129. doi: 10.1002/ana.410300202. [DOI] [PubMed] [Google Scholar]
  18. Liu T., McDonnell P. C., Young P. R., White R. F., Siren A. L., Hallenbeck J. M., Barone F. C., Feurestein G. Z. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke. 1993 Nov;24(11):1746–1751. doi: 10.1161/01.str.24.11.1746. [DOI] [PubMed] [Google Scholar]
  19. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  20. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  21. Murai A., Miyahara T., Fujimoto N., Matsuda M., Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986 Feb;59(2):199–204. doi: 10.1016/0021-9150(86)90048-1. [DOI] [PubMed] [Google Scholar]
  22. Niendorf A., Rath M., Wolf K., Peters S., Arps H., Beisiegel U., Dietel M. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol. 1990;417(2):105–111. doi: 10.1007/BF02190527. [DOI] [PubMed] [Google Scholar]
  23. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H. J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989 Sep-Oct;9(5):579–592. doi: 10.1161/01.atv.9.5.579. [DOI] [PubMed] [Google Scholar]
  24. Ridker P. M., Hennekens C. H., Stampfer M. J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993 Nov 10;270(18):2195–2199. [PubMed] [Google Scholar]
  25. Ross R., Glomset J. A. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med. 1976 Aug 19;295(8):420–425. doi: 10.1056/NEJM197608192950805. [DOI] [PubMed] [Google Scholar]
  26. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20;314(8):488–500. doi: 10.1056/NEJM198602203140806. [DOI] [PubMed] [Google Scholar]
  27. Shintani S., Kikuchi S., Hamaguchi H., Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 1993 Jul;24(7):965–969. doi: 10.1161/01.str.24.7.965. [DOI] [PubMed] [Google Scholar]
  28. Sirén A. L., Liu Y., Feuerstein G., Hallenbeck J. M. Increased release of tumor necrosis factor-alpha into the cerebrospinal fluid and peripheral circulation of aged rats. Stroke. 1993 Jun;24(6):880–888. doi: 10.1161/01.str.24.6.880. [DOI] [PubMed] [Google Scholar]
  29. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  30. Walton K. W., Hitchens J., Magnani H. N., Khan M. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis. 1974 Sep-Oct;20(2):323–346. doi: 10.1016/0021-9150(74)90016-1. [DOI] [PubMed] [Google Scholar]
  31. Woo J., Lau E., Lam C. W., Kay R., Teoh R., Wong H. Y., Prall W. Y., Kreel L., Nicholls M. G. Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke. 1991 Feb;22(2):203–208. doi: 10.1161/01.str.22.2.203. [DOI] [PubMed] [Google Scholar]
  32. Yomantas S., Elner V. M., Schaffner T., Wissler R. W. Immunohistochemical localization of apolipoprotein B in human atherosclerotic lesions. Arch Pathol Lab Med. 1984 May;108(5):374–378. [PubMed] [Google Scholar]
  33. Zenker G., Költringer P., Boné G., Niederkorn K., Pfeiffer K., Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986 Sep-Oct;17(5):942–945. doi: 10.1161/01.str.17.5.942. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES